Dhédin Nathalie, Chamakhi Inès, Perreault Claude, Roy Denis-Claude, Sauvageau Guy, Ducruet Thierry, Busque Lambert, Fish Douglas, Bélanger Robert, Roy Jean
Division of Hematology, Hôpital Maisonneuve-Rosemont, and Université de Montréal, Montreal, Quebec, Canada.
Exp Hematol. 2006 Jan;34(1):107-14. doi: 10.1016/j.exphem.2005.09.013.
Risk factors of acute graft-vs-host disease (GVHD) following allogeneic bone marrow transplantation have been well described before. In this study, we tested the hypothesis that acute GVHD after allogeneic peripheral blood stem cell (PBSC) transplant might be associated with donors' responsiveness to granulocyte colony-stimulating factor (G-CSF), rather than the dose of CD34(+) cells infused.
We retrospectively analyzed mobilization and transplant data (demographic characteristics, donor blood cell subsets after G-CSF, graft composition) in 149 consecutive HLA-identical donor/recipient pairs in order to identify acute GVHD risk factors.
In 25% of donors, G-CSF mobilization led to an outstanding response, defined as greater than 117 x 10(6) CD34(+) cells/L. Overall, incidence of grades II-IV acute GVHD was 20.1% (95% CI: 16.6-23.6). Following univariate analysis, the incidence increased significantly in recipients receiving greater than 10 x 10(6) CD34(+) cells/kg (35% vs 15%; p = 0.007), and those transplanted from outstanding mobilizers (41% vs 12%, p < 0.0001). In multivariate analysis, only transplantation from outstanding mobilizers remained significant (p = 0.02). Donor or recipient demographic characteristics and lymphocyte subsets reinfused in the graft had no impact.
We demonstrate for the first time that donor responsiveness to G-CSF is associated with acute GVHD following PBSC transplantation. If confirmed, this correlation will help to identify recipients who could potentially benefit from improved prophylaxis. As further corollary, decreasing the dose of CD34(+) cells infused is unlikely to prevent acute GVHD. Future studies should focus on the molecular bases of interindividual discrepancies in response to G-CSF.
同种异体骨髓移植后急性移植物抗宿主病(GVHD)的危险因素此前已得到充分描述。在本研究中,我们检验了这样一个假设,即同种异体外周血干细胞(PBSC)移植后的急性GVHD可能与供体对粒细胞集落刺激因子(G-CSF)的反应性有关,而非与输注的CD34(+)细胞剂量有关。
我们回顾性分析了149对连续的HLA匹配的供体/受体对的动员和移植数据(人口统计学特征、G-CSF治疗后的供体血细胞亚群、移植物组成),以确定急性GVHD的危险因素。
在25%的供体中,G-CSF动员导致显著反应,定义为大于117×10(6)个CD34(+)细胞/升。总体而言,II-IV级急性GVHD的发生率为20.1%(95%置信区间:16.6-23.6)。单因素分析后,接受大于10×10(6)个CD34(+)细胞/千克的受体中发生率显著增加(35%对15%;p = 0.007),以及那些接受来自反应显著的动员供体的移植的受体中发生率显著增加(41%对12%,p < 0.0001)。多因素分析中,只有来自反应显著的动员供体的移植仍具有显著性(p = 0.02)。供体或受体的人口统计学特征以及移植物中回输的淋巴细胞亚群没有影响。
我们首次证明供体对G-CSF的反应性与PBSC移植后的急性GVHD有关。如果得到证实,这种相关性将有助于识别可能从改进预防措施中获益的受体。作为进一步的推论,降低输注的CD34(+)细胞剂量不太可能预防急性GVHD。未来的研究应关注个体对G-CSF反应差异的分子基础。